Suprofen

Suprofen
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
Oral, eye drops
ATC code
Legal status
Legal status
  • Discontinued
Pharmacokinetic data
Protein binding20%
Identifiers
  • (RS)-2-[4-(2-thienylcarbonyl)phenyl]propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.050.071 Edit this at Wikidata
Chemical and physical data
FormulaC14H12O3S
Molar mass260.31 g·mol−1
3D model (JSmol)
  • O=C(c1ccc(cc1)C(C(=O)O)C)c2sccc2
  • InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17) ☒N
  • Key:MDKGKXOCJGEUJW-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Suprofen is a nonsteroidal anti-inflammatory drug (NSAID) developed by Janssen Pharmaceutica[1] that was marketed as 1% eye drops under the trade name Profenal.

Uses

Suprofen was originally used as tablet, but oral uses have been discontinued due to renal effects.[2] It was subsequently used exclusively as a topical ophthalmic solution, typically to prevent miosis during and after ophthalmic surgery.[3] This application has been discontinued as well, at least in the US.[4]

References

  1. ^ DE 2353357, Janssen PA, Van Daele GH, Boey JM, "Antiphlogistic aroyl-substituted phenylacetic acid derivatives", issued 1974 
  2. ^ Nies AS (1988). "Renal Effects of Nonsteroidal Anti-Inflammatory Drugs". Basis for Variability of Response to Anti-Rheumatic Drugs. Vol. 24. pp. 95–106. doi:10.1007/978-3-0348-9160-8_9 (inactive 1 November 2024). ISBN 978-3-0348-9931-4. PMID 3142236. {{cite book}}: |journal= ignored (help)CS1 maint: DOI inactive as of November 2024 (link)
  3. ^ "Pharmacy Compounding". Guidance for FDA Staff and Industry Compliance Policy Guides Manual. U.S. Food and Drug Administration. Archived from the original on 1 January 2009.
  4. ^ "Suprofen ophthalmic". Drugs.com. Archived from the original on 2021-09-09. Retrieved 2018-01-23.